Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPVG.L Regulatory News (PVG)

  • There is currently no data for PVG

Trading update

2 May 2017 07:00

RNS Number : 7984D
Premier Veterinary Group PLC
02 May 2017
Β 

PREMIER VETERINARY GROUP PLC

Β 

("PVG", the "Company" or the "Group")

Β 

Trading update following disposal of PVG's Buying Group

Β 

Β 

London, UK, 02 May 2017Β - PremierΒ VeterinaryΒ GroupΒ plcΒ (LSE:Β PVG) provides the following trading update following the disposal of its Buying Group.

Β 

The Group's recurring revenue streams are driven by the number of pets that are signed up to Premier Pet Care Plan ("PPCP"), a preventative healthcare programme for pets. The number of revenue generating pets on activeΒ plans for the second quarter of its 2017 financial year, andΒ inΒ the preceding four quarters was as follows:

Β 

000's

As at

Mar-16

As at

Jun-16

As at

Sept-16

As at

Dec-16

As at

Mar-17

United Kingdom

107

115

121

132

137

Europe

10

14

18

21

22

US

-

-

-

1

2

Β 

Total no of fee generating pets on plan

Β 

117

Β 

129

Β 

139

Β 

154

Β 

161

Β 

Overall, the number of pets on plan has increased by 38% over the corresponding quarter in the previous year and 5% on a quarter by quarter basis.Β 

Β 

On 3rd March 2017 the Company provided an update on its activities in the US conducted through its wholly owned subsidiary, Premier Vet Alliance (US) Limited and expressed its confidence in the prospects for the US business and an intent to significantly increase its investment in sales, launch and business infrastructure to take the opportunity to build market share in future periods. This investment was to be funded by the proposed disposal of the Groups Buying Group.

Β 

On 30 April 2017, PVG announced the agreed disposal of its Buying Group. The additional investment in the US is being made and the number of hospital sign ups and pets on plan continues to increase. During this period of increased activity the Company has identified a number of differences between the UK and US markets necessitating a different approach to certain elements of the provision of preventative healthcare plans in the US. Changes to the business model have been identified and are being actioned and as a consequence it is estimated that a further period of six months may be required until critical mass is achieved in the US.

Β 

Given the strong pipeline of sales, the Board of PVG remains confident that the opportunity to access a significant segment of the available US market still exists. The total number of dogs and cats across the US is estimated at 70 million and 74 million respectively (U.S.Β Pet Ownership & Demographics Sourcebook 2012).

Β 

Trading in the UK and Europe remain in line with expectations.

Β 

PVG expects to release its results for the six months ended 31 March 2017 on 23 May 2017.

Β 

Β 

For further information, please contact:

Β 

Β 

Premier Veterinary Group plc

Tel: +44 (0)117 970 4130

Dominic Tonner, Chief Executive OfficerΒ 

Will Evans, Chief Financial OfficerΒ 

Β 

Β 

Note to Editors:

Β 

PVG's services to third party veterinary practices, through itsΒ wholly-owned subsidiary, Premier Vet Alliance Limited ("PVA"), include the administration and support of a preventative healthcare programme for pets branded "Premier Pet Care Plan" ("PPCP"). In the US, where veterinary practices are known as veterinary hospitals, PPCP is marketed through the Company's wholly-owned subsidiary, Premier Vet Alliance (US)Β Limited.

Β 

PPCPΒ isΒ aΒ structured, preventativeΒ healthcareΒ programmeΒ forΒ cats,Β dogsΒ and rabbits and is available only through veterinary practices/hospitals. The programme is seen as a way of providing gold standard care for pets at an affordable priceΒ forΒ theΒ client, byΒ wayΒ ofΒ fixedΒ monthlyΒ payments.

Β 

PPCPΒ usesΒ aΒ clinicalΒ approachΒ toΒ prevention,Β asΒ thisΒ isΒ theΒ mostΒ effective methodΒ ofΒ ensuringΒ illnessesΒ areΒ diagnosedΒ moreΒ quicklyΒ andΒ notΒ givenΒ a chance to advance. What truly sets PPCP apart is its unique approach of offering an end-to-end solution and support to the practice/hospital, which has been proven to work extremely well. PVA works alongside practices/hospitals to create a tailor-made, cost-effective service for clients, one that delivers excellent care to their patients and significantly improves practice/hospital performance.

Β 

For further details:

Β 

http://www.premiervetgroup.co.uk/

Β 

This announcement includes "forward-looking statements" which include all statements other than statements of historical facts, including, without limitation, those regarding the Company's financial position, business strategy, plans and objectives of management for future operations, and any statements preceded by, followed by or that include forward-looking terminology such as the words "targets", "believes", "estimates", "expects", "aims", "intends", "will", "can", "may", "anticipates", "would", "should", "could" or similar expressions or the negative thereof. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors beyond the Company's control that could cause the actual results, performance or achievements of the Company to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the Company's present and future business strategies and the environment in which the Company will operate in the future. These forward-looking statements speak only as at the date of this announcement. The Company expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward- looking statements contained in this announcement to reflect any change in the Company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. As a result of these factors readers are cautioned not to rely on any forward-lookingΒ statement.

Β 

Β 

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
TSTOKDDPABKDFPK
Date   Source Headline
14th Jun 201011:45 amRNSForm 8.5 (EPT/RI)
14th Jun 20109:16 amRNSForm 8.5 (EPT/NON-RI)
11th Jun 20102:06 pmRNSForm 8.3 - Ark Therapeutics Group PLC
11th Jun 201012:46 pmRNSForm 8.3 - Ark Therapeutics Plc
11th Jun 201010:16 amRNSForm 8.5 (EPT/RI)
11th Jun 20109:52 amRNSForm 8.5 (EPT/NON-RI)
10th Jun 201010:17 amRNSForm 8.5 (EPT/NON-RI)
10th Jun 201010:13 amRNSForm 8.5 (EPT/RI)
9th Jun 201011:38 amRNSForm 8.5 (EPT/RI)
9th Jun 201010:08 amRNSForm 8.5 (EPT/NON-RI)
8th Jun 20104:40 pmRNSSecond Price Monitoring Extn
8th Jun 20104:35 pmRNSPrice Monitoring Extension
8th Jun 201012:36 pmRNSForm 8.3 - Ark Therapeutics
8th Jun 201011:15 amRNSForm 8.5 (EPT/NON-RI)
8th Jun 201011:11 amRNSForm 8.5 (EPT/RI)
7th Jun 20102:53 pmRNSForm 8.3 - Ark Therapeutics Group PLC
7th Jun 201011:55 amRNSForm 8.3 - [Ark Therapeutics Group plc]
7th Jun 201011:04 amRNSForm 8.5 (EPT/RI)-Amendment
7th Jun 201011:04 amRNSForm 8.5 (EPT/RI)
7th Jun 20109:41 amRNSForm 8.5 (EPT/NON-RI)
4th Jun 201012:43 pmRNSForm 8.3 - ARK THERAPEUTICS
4th Jun 201011:43 amRNSForm 8.5 (EPT/RI)
4th Jun 201010:25 amRNSForm 8.5 (EPT/NON-RI)
3rd Jun 20102:53 pmRNSForm 8.3 - Ark Therapeutics Group PLC
3rd Jun 201011:37 amRNSForm 8.5 (EPT/RI)
3rd Jun 201011:25 amRNSForm 8.5 (EPT/NON-RI)
3rd Jun 201010:28 amRNSBlocklisting Interim Review
2nd Jun 20103:07 pmRNSForm 8.3 - Ark Therapeutics Group PLC
2nd Jun 201011:38 amRNSForm 8.5 (EPT/RI)
2nd Jun 20109:22 amRNSForm 8.5 (EPT/NON-RI)
1st Jun 20102:47 pmRNSForm 8.3 - Ark Therapeutics Group PLC
1st Jun 20102:45 pmRNSForm 8.3 - Ark Therapeutics
1st Jun 201010:08 amRNSForm 8.5 (EPT/NON-RI)
28th May 201011:08 amRNSForm 8.5 (EPT/NON-RI)
27th May 20103:17 pmRNSForm 8.3 - Ark Therapeutics Group PLC
27th May 201010:41 amRNSForm 8.5 (EPT/RI)
27th May 20109:04 amRNSForm 8.5 (EPT/NON-RI)
26th May 201011:45 amRNSForm 8.5 (EPT/NON-RI)
25th May 20104:40 pmRNSSecond Price Monitoring Extn
25th May 20104:35 pmRNSPrice Monitoring Extension
25th May 201010:44 amRNSForm 8.5 (EPT/NON-RI)
24th May 20109:10 amRNSForm 8.5 (EPT/NON-RI)
24th May 20107:00 amRNSAppointment of CFO and Company Secretary
21st May 20103:32 pmRNSForm 8.5 (EPT/RI)
21st May 20109:55 amRNSForm 8.5 (EPT/NON-RI)
20th May 20109:50 amRNSForm 8.5 (EPT/NON-RI)
19th May 201010:48 amRNSForm 8.5 (EPT/NON-RI)
18th May 201011:05 amRNSForm 8.5 (EPT/NON-RI)
18th May 201010:11 amRNSForm 8.5 (EPT/RI)
18th May 20107:00 amRNSInterim Management Statement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.